What makes someone stop a lung fibrosis drug? a study asks patients directly
NCT ID NCT07722507
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This study uses web-based interviews to explore how adults in Japan with pulmonary fibrosis decide whether to continue or stop antifibrotic therapy after experiencing side effects. Researchers aim to understand the personal and psychological factors behind these decisions. The findings may help improve shared decision-making between patients and doctors.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- antifibrotic therapy (pirfenidone, nintedanib, or nerandomilast)
- What this could lead to
- If successful, this could help doctors and patients make better-informed decisions about continuing or stopping antifibrotic treatment after side effects.
- What could go wrong
- This is a small, qualitative interview study in Japan only, so findings may not apply to other populations or settings. It does not test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population will include adults diagnosed with pulmonary fibrosis (PF) in Japan who have a history of taking, or are currently taking, pirfenidone, nintedanib, or nerandomilast treatment who have experienced treatment related adverse events.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Participants must meet all the following criteria to be eligible for inclusion in this study: 1. Pulmonary fibrosis (PF) participants in Japan. Note: This includes those clinically recognized as having idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). 2. Participants who are ≥18 years of age at the time of providing informed consent via the web-based system. 3. Participants receiving outpatient care for pulmonary fibrosis (PF) who have been introduced to this study by a referring physician. 4. Participants who have a history of taking, or are currently taking, pirfenidone, nintedanib, or nerandomilast. 5. Participants who have experienced at least one antifibrotic (AF) therapy-related adverse event (AE). * Discontinuation group only 1\) Participants who have not received AF therapy for at least 1 month prior to enrollment. 2\) Participants whose AF therapy was discontinued within 6 months prior to enrollment. 3\) Participants whose reason for discontinuing AF therapy includes at least one AF therapy-related AE. * Continuation group only 1. Participants who feel or have felt burdened by the experienced AE. 2. Participants who have continued AF therapy for a specific period (≥6 months) at the time of enrollment. Exclusion Criteria: Participants meeting any of the following criteria will be excluded from the study: <!-- --> 1. Participants currently participating in any interventional clinical trials (regardless of the study drug, excluding observational studies). 2. Participants who have undergone lung transplantation. * Discontinuation group only 1) Participants who discontinued AF therapy solely for reasons other than AE (e.g., financial reasons, disease progression).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Idiopathic pulmonary fibrosis are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Mebix, Inc.
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Efficacy of diaphragmatic release technique versus targeted inspiratory muscle training on pulmonary function and functional capacity in patients with stable pulmonary fibrosis: a randomized controlled trial
- Inhaled therapy aims to slow the march of progressive pulmonary fibrosis
- Can a thousand patient records unlock better care for a rare lung disease?
- Sharper CT scans may solve a lung disease diagnostic puzzle
- Can mindfulness ease the emotional toll of pulmonary fibrosis?
- Can we untangle the overlap of lung diseases? a new study aims to find out